Mankind Pharma Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Mankind Pharma Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹1,080
Per ShareLot Size
13 Shares
Minimum Investment
₹14,040
Issue Size
₹4,326.36 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Mankind Pharma Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
67.29%
Issue Type
Book Building
ISIN
INE634S01028
About the Company
Mankind Pharma Ltd is India's fourth largest pharmaceutical company in terms of Domestic Sales and second largest in terms of sales volume for the Financial Year 2022. The Company is focused on the Indian domestic market, where it develops, manufactures and markets a diverse range of pharmaceutical formulations as well as several consumer healthcare products. In its domestic pharmaceuticals business, it is present across acute and chronic therapeutic areas in India, including antiinfectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/ minerals/ nutrients and respiratory, among others. In its consumer healthcare business, it has established several brands in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and antiacne preparations categories.
Industry Overview
The size of the Indian pharmaceutical market increased at a CAGR of approximately 10.88% from Rs. 660.53 billion in the Financial Year 2012 to Rs. 1,854.98 billion in the Financial Year 2022, and is forecast to further grow at a CAGR of 10% - 11% to reach Rs. 3,000 - Rs. 3,100 billion by the Financial Year 2027. The key factors affecting the growth of the IPM are rising income levels, increasing life expectancy, growth in lifestyle diseases and government initiatives. The consumer healthcare market in India has witnessed and is expected to continue to witness value growth in the range of 10-11%, mainly driven by new lifestyle patterns leading to disorders/diseases, consumer awareness on preventive healthcare, and an increase in consumer income level and expenditure on consumer healthcare products.
Company History
Mankind Pharma Limited was incorporated on July 3, 1991, as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of the Company to a public limited company and as approved by its Shareholders pursuant to a special resolution dated July 14, 2005, the name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.
Products & Services
- The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Growth Strategy
- Increase Covered Market presence including in chronic therapeutic areas
- Focus on increasing penetration in metro and Class I cities
- Focus on building alternative channels for growth
- Grow its consumer healthcare business
- Continue to develop and invest in digital platforms to enhance doctor engagement
Customer Base
Wholesalers and Retailers
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 40,058,844 equity shares of face value of Re. 1 each ("Equity Shares") of Mankind Pharma Limited ("The Company" or the "Issuer") for cash at a price of Rs. 1,080 per equity share ("Offer Price") aggregating to Rs. 4326.36 crores, comprising an offer for sale of 3,705,443 equity shares aggregating to Rs. 400.18 crores by Ramesh Juneja, 3,505,149 equity shares aggregating to Rs. 378.56 crores by Rajeev Juneja, 2,804,119 equity shares aggregating to Rs. 302.85 crores by Sheetal Arora (collectively, the "Promoter Selling Shareholders"), 17,405,559 equity shares aggregating to Rs. 1879.80 crores by Cairnhill Cipef Limited, 2,623,863 equity shares aggregating to Rs. 283.38 crores by Cairnhill CGPE Limited, 9,964,711 equity shares aggregating to Rs. 1076.19 crores by Beige Limited and 50,000 equity shares aggregating to Rs. 5.40 crores by Link Investment Trust (collectively, the "Investor Selling Shareholders") (the "Promoter Selling Shareholders" and the "Investor Selling Shareholders", together, the "Selling Shareholders") (the "Offer for Sale" or the "Offer"). The offer shall constitute 10% of the post-offer paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- scaled domestic focused business with potential for further growth;
- growing faster than the rate of the IPM with a focus on volume-led growth;
- diversified portfolio with market leading rankings across key therapeutic areas;
- established and growing consumer healthcare franchise with brand recall;
- leveraged its corporate brand to build and scale brands;
- The company is subject to extensive government regulations which are also subject to change. If the company fail to comply with the applicable regulations prescribed by the governments and the relevant regulatory agencies, its business, financial condition, cash flows and results of operations will be adversely affected.
- The company is required to obtain, maintain or renew its statutory and regulatory approvals, licenses, and registrations to operate its business.
- Any disruption, slowdown or shutdown in its manufacturing or R&D operations could adversely affect its business, financial condition, cash flows and results of operations.
- The company inability to accurately forecast demand for its products and manage the company inventory may have an adverse effect on its business, financial condition, cash flows and results of operations.
- Any failure to maintain and enhance, or any damage to, its brands, product image or reputation could adversely affect the market recognition of, and trust in, the company products.